1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
RxElite, Inc.

RxElite, Inc.

RXEI
RxElite, Inc.US flagOther OTC
0.00
USD
- -
- -
1,483.00Market Cap
RxElite, Inc.
RXEI
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2004
2005
2006
2007
TTM
FRC
- -
0.1
0.11
0.05
0.09
Revenue per Share
- -
- -
0.01
-0.27
-0.25
Basic EPS, GAAP
- -
- -
0.01
-0.24
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
0.01
0.02
-0.46
-0.46
Book Value per Share
- -
0.01
0.02
0.2
-0.02
Tangible Book Value per Share
- -
10
10
62
116
Basic Weighted Avg Shares
1
1
1
3
10
Sales/Revenue/Turnover
100
-3.71
12.24
-436.8
-100.51
Operating Margin (%)
- -
- -
- -
- -
5
Depreciation Expense
- -
- -
- -
-17
-29
Net Income, GAAP
- -
- -
34.73
- -
- -
Effective Tax Rate (%)
-4.11
-3.71
7.99
-610.52
-280.07
Profit Margin (%)
- -
- -
- -
11
-3
Working Capital
- -
- -
- -
- -
7
LT Debt
- -
- -
- -
12
14
Total Equity
- -
- -
66.46
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-76.27
66.46
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'08
Jun'08
Sep'08
ST Debt
- -
3
- -
LT Borrowings
1
3
7
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
116
116
120
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'08
Jun'08
Sep'08
Total Current Assets
14
15
8
Cash, Cash Equivalents & STI
1
3
1
Accounts Receivable, Net
2
2
1
Inventories
10
10
5
Total Current Liabilities
13
17
12
Payables & Accruals
11
12
9
ST Debt
- -
3
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
6,422.13%
Free Cash Flow
- -
- -
-25,487.88%
Net Income, GAAP
- -
- -
-18,363.65%
Sales/Revenue/Turnover
- -
- -
138.97%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
1
2007
1
- -
- -
1
3
2008
3
3
3
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
0.01
2007
- -
0.01
- -
-0.04
-0.27
2008
-0.06
-0.05
-0.09
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -
Similar Companies
Jiuzhitang Co., Ltd. (000989.SZ)
Hikma Pharmaceuticals PLC (HKMPF)
Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS)
Evotec SE (EVT.SW)
North Springs Resources Corp (NSRS)
JW Pharmaceutical Corporation (001065.KS)
Business
RxElite, Inc. engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets. Its main product offerings include sterile liquid dose products such as generic ophthalmic products in unit and multi-dose presentations, sterile unit dose inhalation respiratory products, injectable drugs, and active pharmaceutical ingredients (APIs). The company serves customers including hospitals and hospital group purchasing organizations, national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, outpatient surgery centers, and ambulatory care clinics. RxElite operates geographically across the United States, Europe, and Asia through its subsidiaries. Founded in Meridian, Idaho, RxElite is a subsidiary of Piramal Healthcare Ltd. In recent developments, the company has expanded its product capabilities by acquiring FineTech Laboratories, Ltd., which specializes in complex API manufacture, thus significantly enhancing its production of difficult formulations. Additionally, RxElite sold its inhalation anesthetic gas distribution business to Piramal Healthcare Limited to focus on its core specialty generic markets and advanced pharmaceutical manufacturing.